nivolumab biosimilar / Orion Corp, Shilpa Medicare - LARVOL DELTA

Orion Pharma…and Shilpa Biologicals Private Limited…have entered into an agreement to commercialise intravenous (iv) nivolumab biosimilar in Europe (Orion Press Release) - "Shilpa’s nivolumab biosimilar is currently under development by the company. Under the terms of the agreement, Orion will gain exclusive right to distribute, market and sell Shilpa’s iv nivolumab biosimilar in Europe. Shilpa will supply the product to Orion, and is entitled to receive from Orion certain development and regulatory milestone payments."

Licensing / partnership • Solid Tumor